STOCK TITAN
  1. Home
  2. News
  3. ALGS

Aligos Therapeutics Inc - ALGS STOCK NEWS

Welcome to our dedicated news page for Aligos Therapeutics (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aligos Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aligos Therapeutics's position in the market.

News
Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
Rhea-AI Summary
Aligos Therapeutics, Inc. (Nasdaq: ALGS) will present at the 2023 Piper Sandler Healthcare Conference in New York on November 30, 2023, at 12:30 p.m. ET. Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO, will be the presenter. The webcast link and replay details are available on the Aligos investor section of the website. The management team will also participate in investor 1x1 meetings during the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.19%
Tags
conferences
-
News
Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile
Rhea-AI Summary
Aligos Therapeutics, Inc. (Nasdaq: ALGS): ALG-055009, a thyroid hormone receptor-beta (THR-b) drug, demonstrated favorable PK in a Phase 1 study, lowering lipid levels in hypercholesterolemic subjects. The drug is more potent and selective than existing treatments, supporting its progression into a 12-week Phase 2a study in NASH patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.16%
Tags
clinical trial
-
News
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
Rhea-AI Summary
ALG-000184 Shows Promising Results in Reducing HBV Antigens and DNA Levels, Aligos Therapeutics Announces
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.22%
Tags
none
News
Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule, and Updates on Several Preclinical Candidates for the Treatment of Chronic Hepatitis B, in Addition to the Recently Announced Late Breaker Poster (#5028-C)
Rhea-AI Summary
Aligos Therapeutics, Inc. will present six posters at the American Association for the Study of Liver Diseases’ The Liver Meeting 2023, showcasing clinical and preclinical data on their NASH and CHB programs, including Phase 2-enabling studies and liver targeted oral PD-L1 small molecule inhibitor discovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
conferences
-
News
Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data
Rhea-AI Summary
Aligos Therapeutics, Inc. will host a virtual KOL event featuring Mark Sulkowski, MD, to review the Late Breaking results and next steps for its Phase 1 CAM-E drug candidate for chronic Hepatitis B (CHB). The event will take place on November 16, 2023, at 1:30 PM ET. The Phase 1 data will also be presented at the Liver Meeting® on November 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
-
News
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
Rhea-AI Summary
Aligos Therapeutics reported recent business progress and financial results for Q3 2023. They raised $92 million in private placement financing, received clearance for their first US IND, and secured an $8.5 million contract with the NIAID. They are well positioned to advance their clinical programs in NASH, CHB, and coronavirus protease inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
earnings
News
Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023
Rhea-AI Summary
Aligos Therapeutics to report Q3 2023 financial results on November 2, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
none
-
News
Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting® 2023
Rhea-AI Summary
Aligos Therapeutics announces acceptance of abstract for its drug candidate ALG-000184 at The Liver Meeting®
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
conferences
-
News
Aligos Therapeutics Announces $92 Million Private Placement Financing
Rhea-AI Summary
Aligos Therapeutics, Inc. has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $92 million. The proceeds will be used to fund the advancement of its drug candidates, including the Phase 2a NASH study and the CAM-E candidate. The company believes the funding will extend its cash runway through the end of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.58%
Tags
none
News
Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558
Rhea-AI Summary
Aligos Therapeutics has been awarded an $8.5 million NIAID contract to advance its pan-coronavirus protease inhibitor ALG-097558 into future Phase 2/3 studies. This is the second NIH-funding received for the development of novel inhibitors of the coronavirus 3CL protease. ALG-097558 has shown potent inhibition against various forms of coronavirus, including SARS-CoV-2. The non-dilutive external funds will enable Aligos to continue advancing the ALG-097558 program beyond the ongoing Phase 1 study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock ALGS logo
Aligos Therapeutics Inc

Nasdaq:ALGS

ALGS Rankings

#4592 Ranked by Market Cap
#4378 Ranked by Stock Gains
N/A Ranked by Dividends

ALGS Stock Data

63.18M
36.68M
21.07%
62.52%
1.15%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
South San Francisco

About ALGS

aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, a oligonucleotide for the treatment of chb; alg-125097, an sirna drug candidate to treat chb; and alg-055009, a small molecule thr-㟠agonist for the treatment of non-alcoholic steatohepatitis. aligos therapeutics, inc. was founded in 2018 and is headquartered in south san francisco, california.